We are building a global network of leading consumer healthcare partners who are well resourced to commit significant marketing investment and expertise.
Haleon - USA
Futura entered into a licensing agreement with world leading consumer healthcare Company Haleon (previously GSK Consumer Healthcare) for the rights to exclusively commercialise Eroxon® in the USA.
Haleon is responsible for all investment activities related to the launch and marketing of the product in the USA, with Futura providing ongoing technical support for OTC product development and commercialisation opportunities.
Eroxon® US site: www.eroxon.us
Cooper Consumer Health ("Cooper") - European Economic Area, United Kingdom and Switzerland
Cooper is a leading European independent self-care organisation, and has the rights to commercialise Eroxon® throughout the European Economic Area (“EEA”), the United Kingdom and Switzerland. The original agreement was for an initial term of five years but was extended in January 2024 to last for five years until January 2029. Futura remains legal manufacturer and is responsible for the supply of Eroxon®, through its third-party contract manufacturers.
Eroxon® European site: www.eroxon.eu
M8 Pharmaceuticals Inc ("M8") - Central and South America
Specialty pharmaceutical company M8 Pharmaceuticals, an Acino Company, has the rights to exclusively develop and commercialise Eroxon®, in Central and South America, including Brazil which is the largest market for prescription treatments for erectile dysfunction. In November 2023 the agreement was extended from Brazil and Mexico to the rest of the Central and South American region. M8 is responsible for all costs related to the regulatory approval and marketing of the product. Futura provides reasonable ongoing technical support for OTC product development and commercialisation.
Eroxon® Mexican site: www.eroxon.mx
Labatec Pharma ("Labatec") - Gulf Co-operation Council ("GCC") region and Middle East
Swiss-based specialty pharma company Labatec has the rights to exclusively commercialise Eroxon® in the GCC region as well as Jordan, Lebanon and Iraq. The initial licence agreement term is for eight years with the ability to extend for successive two-year terms by mutual consent.